![Matej Mikulic](https://cdn.statcdn.com/static/../CMS/contactperson/ERI285_1713877581.png)
Novo Nordisk sales in diabetes subsegments 2023
Danish drug manufacturer Novo Nordisk's diabetes subsegment of glucagon-like peptide 1 (GLP-1) products generated more than 123 billion kroner in 2023. The company's total insulin-related sales stood at some 48 billion kroner, of which fast-acting insulins made up the largest share.